Literature DB >> 1674015

Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia.

C F LeMaistre1, M G Rosenblum, J M Reuben, D R Parkinson, C M Meneghetti, K Parker, J P Shaw, A B Deisseroth, T Woodworth.   

Abstract

In DAB486IL-2 the receptor-binding domain of native diphtheria toxin is replaced by human IL-2 sequences. This recombinant fusion protein is selectively cytotoxic for cells bearing high-affinity IL-2 receptors--eg, leukaemic cells. A patient with chronic lymphocytic leukaemia who did not respond to gamma interferon and conventional antileukaemic drugs has responded to DAB486IL-2.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1674015     DOI： 10.1016/0140-6736(91)92788-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  4 in total

Review 1.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

2.  Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes.

Authors:  A Bousvaros; A C Stevens; T B Strom; J Murphy; J T Lamont
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

Review 3.  Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.

Authors:  Robert J Kreitman
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

4.  Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.

Authors:  John H Sampson; Gamal Akabani; Gary E Archer; Darell D Bigner; Mitchel S Berger; Allan H Friedman; Henry S Friedman; James E Herndon; Sandeep Kunwar; Steve Marcus; Roger E McLendon; Alison Paolino; Kara Penne; James Provenzale; Jennifer Quinn; David A Reardon; Jeremy Rich; Timothy Stenzel; Sandra Tourt-Uhlig; Carol Wikstrand; Terence Wong; Roger Williams; Fan Yuan; Michael R Zalutsky; Ira Pastan
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.